Go to deals
Healthcare

Grupo Auguri has acquired a controlling interest in Clínica Las Condes S.A.

Grupo Auguri has acquired a controlling interest in Clínica Las Condes S.A.

Grupo Auguri is a Chilean family office linked to the Karlezi Solari family, which have investments in multiple companies from various industries throughout the country and abroad.

Based in Santiago, Clínica Las Condes is one of the largest private hospitals in Chile. The company initiated its operations in 1982 with a focus on high complexity medicine. Its services include inpatient medical, surgical intensive care units, intermediate, adult, pediatric, neonatal, surgical wards, post-recovery operative, clinical laboratories, radiology, CT magnetic resonance imaging, radiation therapy, PET-CT, nuclear medicine, ultrasound, dialysis and other services that include outpatient procedures.

Oaklins’ team in Chile acted as financial advisor to Grupo Auguri in this transaction.

Service
M&A buy-side
Parties

Talk to the deal team

 Raimundo  Silva

Raimundo Silva

Partner

Santiago, Chile
Oaklins LarrainVial
 Alberto  del Pedregal

Alberto del Pedregal

Analyst

Santiago, Chile
Oaklins LarrainVial

Related deals

Groupe Nature acquires Winco
Consumer & Retail | Healthcare

Groupe Nature acquires Winco

Groupe Nature has signed an agreement with Nicolas Watine, founder and CEO of Winco, to acquire his stake in the comany. It specializes in the distribution of health and cosmetic products in parapharmacies affiliated to supermarket chains. This acquisition strengthens Groupe Nature’s position as a multi-channel specialist in the distribution of organic health products.

Learn more
Camelia pharmacy chain has been acquired by Medigate Management UAB
Consumer & Retail | Healthcare

Camelia pharmacy chain has been acquired by Medigate Management UAB

CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.

Learn more
Shield Therapeutics has raised funds
Healthcare

Shield Therapeutics has raised funds

Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.

Learn more